Industry Wire 214

September 27, 2024 Jake Fishman 0 min read
  1. LAPD officer’s gun sucked into MRI machine during raid.
  2. Dems introduce legislation to permanently lower ACA plan costs. 
  3. Cardinal Health acquires Integrated Oncology Network for $1B.
  4. CDC: 40.3% of U.S adults are obese, 46.5% of adults aged 40-59.
  5. VA’s new Oracle EHR saw 826 ‘major’ incidents since its launch.
  6. U.S. House committee passes rare pediatric disease drug bill.
  7. 29% of Americans have undiagnosed iron deficiency.
  8. Senate holds Steward Health CEO in criminal contempt.
  9. PA-based system fires workers for sharing inappropriate patient images.
  10. Providers say reimbursement denials are getting worse.
Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Atrial Fibrillation November 10, 2025

ARREST-AF and the Importance of Lifestyle Post-Ablation November 10, 2025

Catheter ablation for atrial fibrillation might be missing half its potential, after results from the ARREST-AF trial demonstrated that structured lifestyle and risk factor management significantly increases a patient’s 12-month freedom from arrhythmia while cutting recurrence risk nearly in half. That could be changing now, thanks to the ARREST-AF trial which randomized 122 patients with […]

Heart Failure November 6, 2025

PREVENT-TAHA8 Supports Stem Cells for Post-MI HF November 6, 2025

Stem cell therapy for post-MI heart failure might deserve a second look, after the PREVENT-TAHA8 trial demonstrated that mesenchymal stem cell infusion within days of STEMI significantly reduced 3-year HF incidence. Based in Iran, the PREVENT-TAHA8 trial, randomized 396 patients following LAD STEMI with LVEF <40%, to receive either an intracoronary mesenchymal stem cell infusion […]

Structural Heart November 3, 2025

Abbott’s Tendyne TMVR System Works Even in the Sickest MR Patients November 3, 2025

New research presented at TCT 2025 suggests that Abbott’s FDA-approved Tendyne TMVR system leads to significantly better health outcomes in patients with severe mitral annular calcification who were previously considered untreatable. The SUMMIT-MAC trial enrolled 103 patients with severe MAC and found that the challenging patient population showed strong outcomes despite extreme pathology… However, patients […]